Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/28/2022 | $15.00 → $1.00 | Buy → Hold | Stifel |
| 10/13/2021 | $15.00 | Buy | Stifel |
SC 13G/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)
SC 13G/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)
SC 13G/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)
Stifel downgraded PhaseBio Pharmaceuticals from Buy to Hold and set a new price target of $1.00 from $15.00 previously
Stifel resumed coverage of PhaseBio Pharmaceuticals with a rating of Buy and set a new price target of $15.00
Needham reiterated coverage of PhaseBio Pharmaceuticals with a rating of Buy and set a new price target of $15.00 from $16.00 previously
4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)
4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)
4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)
8-K - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)
NT 10-Q - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)
8-K - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)
Bidding Process and Auction Projected to Conclude December 2022 PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. As part of the case, PhaseBio also intends to file a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code. The proposed bidding procedures, if approved by the court, would require interested parties to submit binding offers
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an update on corporate activities. "The second quarter of 2022 marked a period of continued progress for PhaseBio," said Jonathan Mow, Chief Executive Officer of PhaseBio Pharmaceuticals. "Following a successful meeting with the U.S. Food and Drug Administration (FDA) during our pre-biologics license application (pre-BLA) meeting earlier this year and as previously disclosed, we have been focused on clinical developmen
Held successful Type B pre-biologics license application (BLA) meeting with U.S. FDA for future submission of BLA for bentracimab BLA submission for bentracimab is planned for early in the fourth quarter of 2022 and PhaseBio is preparing for commercialization in U.S., if approved Presented positive results from Phase 2b trial for bentracimab at ACC.22 Completed the Process Performance Qualification (PPQ) campaign demonstrating commercial scale manufacturing ability for bentracimab PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financia
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Jonathan J. Birchall as Chief Commercial Officer. "Jonathan brings to PhaseBio deep commercial expertise in the critical-care setting, which he gained through his leadership of the thrombolytics franchise at Genentech," said Jonathan P. Mow, Chief Executive Officer of PhaseBio. "With his background and track record of success, Jonathan has the experience necessary to lead our commercial organization and joins us at a pivotal time in PhaseBio's evolution as we begin prepar
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of William D. Humphries to its board of directors. Additionally, Justin Klein, M.D., J.D., is stepping down from his role as director, effective immediately. "Bill's deep commercial expertise gained through his leadership roles at numerous specialty pharmaceutical companies will be an invaluable addition to our already robust board of directors," said Jonathan P. Mow, Chief Executive Officer of PhaseBio. "Bill joins us at an exciting and pivotal time in PhaseBio's growth, as
PhaseBio recently received formal written minutes from the FDA following its Pre-BLA Meeting held in early April and is expecting to submit its Biologics License Application (BLA) by early in the fourth quarter of 2022 The FDA indicated willingness to accept a BLA with data from 25-30 uncontrolled bleeding patients, in addition to surgical patients enrolled to date, to potentially support a label that includes both surgical and uncontrolled bleeding indications To date, PhaseBio has enrolled 35 uncontrolled bleeding patients and has completed enrolling surgical patients in the Phase 3 REVERSE-IT trial Conference call and webcast today at 8:30 a.m. ET PhaseBio Pharmaceuticals, Inc. (NASD
Global Phase 3 trial of bentracimab achieved primary reversal endpoint with immediate and sustained reversal of the antiplatelet effects of ticagrelor in both surgical and bleeding populations Co-primary endpoint of clinical hemostasis achieved in greater than 90% of patients Bentracimab appeared well tolerated with no drug-related serious adverse events Results presented today in Late-Breaking Science Session at the American Heart Association's 2021 Scientific Sessions and accepted for publication in NEJM Evidence, a new digital journal from the NEJM (New England Journal of Medicine) Group Investor webcast scheduled for today at 12:30 p.m. ET PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHA
Prespecified interim analysis of pivotal REVERSE-IT Phase 3 trial to be presented during late-breaking science session on November 15th at the American Heart Association's Scientific Sessions 2021 Guest speakers include Deepak L. Bhatt, M.D., MPH; Charles Pollack, M.D.; and Philippe Gabriel Steg, M.D. Video webcast to be held on November 15, 2021, at 12:30 p.m. ET (9:30 a.m. PT) PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it will host an investor call on November 15, 2021, at 12:30 p.m. ET (9:30 a.m. PT) to discuss the results
On Thursday, shares of PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) experienced volatile short activity. After the activity, the stock price went down -16.67% to $0.06. The overall sentiment for PHAS has been Bearish. The signal from the volatility alert is trending Bearish. Therefore, the recommendation is to Strong Sell. The volatility alert was produced on the prior trading date, 11/3/2022 with a volatility change of +59.07%. The current volatility indicator stands at 14.179. Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the purpose of providing liquidity to short sellers.
Gainers Starry Group Holdings, Inc. (NYSE:STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results. Benefitfocus, Inc. (NASDAQ:BNFT) shares surged 48.2% to settle at $10.36 on Wednesday after the company announced it will be acquired by Voya Financial for $10.50 per share. Forza X1, Inc. (NASDAQ:FRZA) climbed 45% to close at $2.45 after the company announced it received 50 electric boat reservations in the last 90 days, potentially resulting in over $8.5 million in revenue. Bandwidth Inc. (NASDAQ:BAND) rose 41.6% to close at $17.42 after the company reported better-than-expected Q3 sales results. The company also issued Q4 and FY22 sales guidance above analyst estima
Gainers Starry Group Holdings, Inc. (NYSE:STRY) gained 56% to $0.2808 after reporting Q3 results. Benefitfocus, Inc. (NASDAQ:BNFT) shares jumped 47.8% to $10.33 after the company announced it will be acquired by Voya Financial for $10.50 per share. Akso Health Group (NASDAQ:AHG) gained 44% to $0.7280. Rayonier Advanced Materials Inc. (NYSE:RYAM) shares climbed 40.9% to $6.30 as the company posted upbeat quarterly results. Forza X1, Inc. (NASDAQ:FRZA) jumped 39% to $2.3495 after the company announced it received 50 electric boat reservations in the last 90 days, potentially resulting in over $8.5 million in revenue. Bandwidth Inc. (NASDAQ:BAND) gained 36.9% to $16.84 after the compan